Author:
Al-Mamari Said Abdallah,Al-Busaidy Salim Said
Publisher
Springer International Publishing
Reference19 articles.
1. Sèbe P, Rigaud J, Avancès C et al. Les membres de l’AFCE; Les membres du CCAFU. CCAFU’s contribution to the French National Cancer Institute’s reference frame: adrenal malignant tumours. Prog Urol. 2013;23(Suppl 2):S167–74.
2. Szolar DH, Korobkin M, Reittner P, et al. Adrenocortical carcinomas and adrenal pheochromocytomas: mass and enhancement loss evaluation at delayed contrast-enhanced CT. Radiology. 2005;234:479–85.
3. Slattery JM, Blake MA, Kalra MK, Misdraji J, Sweeney AT, Copeland PM, Mueller PR, Boland GW. Adrenocortical carcinoma: contrast washout characteristics on CT. AJR Am J Roentgenol. 2006;187(1):W21–4.
4. Sturgeon C, Shen WT, Clark OH, Duh QY, Kebebew E. Risk assessment in 457 adrenal cortical carcinomas : how much does tumour size predict the likelihood of malignancy ? J Am Coll Surg. 2006;202:423–30.
5. Mege D, Taieb D, Lowery A, Loundou A, DE Micco C, Castinetti F, Morange I, Henry JF, Sebag F. Contemporary review of large adrenal tumours in a tertiary referral center. Anticancer Res. 2014;34(5):2581–8.